Immunosuppression Following Venous Allografts Transplantations – The Authors’ experience

Česká verzia

Authors: M. Adamec; I. Matia; L. Janoušek
Authors place of work: KTCH IKEM Praha, přednosta: prof. MUDr. Miloš Adamec, CSc.
Published in the journal: Rozhl. Chir., 2011, roč. 90, č. 2, s. 130-133.
Category: Monothematic special - Original

Summary

Aim:
Venous and arterial graft usage in vascular reconstructions was re-discovered in connection with organ transplantation development. Allografts are employed in many clinics, however, uniform opinion on the use of immunosuppression after the procedure of venous graft transfer from a cadaveric donor, is still lacking.

Material and Methods:
The authors present their own group of patients who underwent vascular reconstructions, and in whom allogenic vein was used. The majority of indications for bypass procedures resulted from critical limb ischemia. Immunosuppressive medication was administered during the vascular procedure and, over the past several years, it purely consisted of tacrolimus monotherapy.

Results:
In the group of 101 patients, no serious complications due to adverse effects of immunosuppresion therapy were recorded.

Key words:
immunosuppression – venous allograft – transplantation – critical limb ischemia

Zdroje

1. Hejnal, J., Krajíček, M., Zástava, V. Cévní náhrady. Academia, 1967.

2. Lopez-Cepero, M., Sanders, C. E., Buggs, J., et al. Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts. Transplantation, 2002; 73: 817–819.

3. Prager, M., Holzenbein, T., Aslim, E., et al. Fresh arterial homograft transplantation: A novel concept for critical limb ischaemia. Eur. J. Vasc. Endovasc. Surg., 2002; 24: 314–321.

4. Madden, R., Lipkowitz, G., Benedetto, B., et al. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. Am. J. Kidney Dis., 2002; 40: 1240–1243.

5. Bandlien, K. O., Toledo-Pereyra, L. H., MacKenzie, G. H., et al. Immunosuppression with cyclosporine. A new approach to improve patency of venous allografts. Arch. Surg., 1983; 118: 829–833.

6. Zoja, C., Furci, L., Ghilardi, F., et al. Cyclosporin-induced endothelial cell injury. Lab. Invest., 1986; 55: 455–462.

7. Khanna, A., Kapur, S., Sharma, V., et al. In vivo hyperexpression of transforming growth factor-beta1 in mice: Stimulation by cyclosporine. Transplantation, 1997; 63: 1037–1039.

8. Azuma, N., Sasajima, T., Kubo, Y. Immunosuppression with fk506 in rat arterial allografts: Fate of allogeneic endothelial cells. J. Vasc. Surg., 1999; 29: 694–702.

9. Matia, I., Varga, M., Lodererova, A., et al. The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats. Eur. J. Vasc. Endovasc. Surg., 39: 478–484.

10. Matia, I., Lodererova, A., Adamec, M. Delayed administration of fk506 is sufficient to suppress acute rejection changes after aortal transplantation in rats. Transpl. Int., 2007; 20: 371–380.